Shrivastava Agnivesh R, Ursekar Bhalchandra, Kapadia Chhanda J
Department of Pharmaceutics, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai-400098, India.
Curr Drug Deliv. 2009 Jan;6(1):28-37. doi: 10.2174/156720109787048258.
The objective of the present work undertaken was to enhance the solubility and dissolution rate of valsartan a poorly water soluble antihypertensive, by preparation of solid dispersion granules which would additionally allow easy compression into tablets. The dispersion granules were prepared using a hot melt granulation technique which involved preparation of a homogenous dispersion of valsartan in gelucire-50/13 melt, followed by its adsorption on to the surface of aeroperl-300pharma, an inert adsorbent. A two-factor, three-level (32) statistical design was implemented to quantitate the influence of gelucire-50/13 and aeroperl-300pharma on the dissolution profile and flow properties of the dispersion granules, where gelucire-50/13 and aeroperl-300pharma were chosen as independent variables, while dissolution and flow properties were chosen as dependent variables. The dispersion granules were characterized for their in-vitro dissolution rate and flow properties. An appropriate statistical model was arrived at and a significantly enhanced dissolution rate and flow properties were exhibited with the optimized formulation. The formulation was further characterized by FTIR, DSC, XRD and SEM analysis. FTIR spectrum revealed some drug excipient interactions. DSC and XRD data indicated the retention of amorphous form of valsartan. SEM confirmed the homogeneity and surface adsorption of the gelucire-50/13 melt on aeroperl-300pharma leading to enhanced surface area and thus dissolution rate. The tablets of optimized dispersion granules were formulated and evaluated. The in-vitro dissolution rate of these tablets was significantly better in comparison with marketed formulation. In conclusion the statistical model enabled us to understand the effects of formulation variables on the dispersion granules of valsartan.
本研究的目的是通过制备固体分散体颗粒来提高缬沙坦(一种水溶性差的抗高血压药物)的溶解度和溶出速率,该颗粒还易于压制成片剂。采用热熔制粒技术制备分散体颗粒,该技术包括将缬沙坦在 Gelucire-50/13 熔体中制备成均匀分散体,然后将其吸附到惰性吸附剂 Aeroperl-300pharma 的表面。采用二因素三水平(3²)统计设计来定量 Gelucire-50/13 和 Aeroperl-300pharma 对分散体颗粒溶出曲线和流动性质的影响,其中将 Gelucire-50/13 和 Aeroperl-300pharma 选为自变量,而溶出度和流动性质选为因变量。对分散体颗粒的体外溶出速率和流动性质进行了表征。得出了合适的统计模型,优化后的制剂表现出显著提高的溶出速率和流动性质。通过傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)、X 射线衍射(XRD)和扫描电子显微镜(SEM)分析对该制剂进行了进一步表征。FTIR 光谱显示了一些药物与辅料的相互作用。DSC 和 XRD 数据表明缬沙坦保持无定形形式。SEM 证实了 Gelucire-50/13 熔体在 Aeroperl-300pharma 上的均匀性和表面吸附,从而增加了表面积,进而提高了溶出速率。对优化后的分散体颗粒片剂进行了制备和评价。与市售制剂相比,这些片剂的体外溶出速率明显更好。总之,统计模型使我们能够了解制剂变量对缬沙坦分散体颗粒的影响。